Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins
Open Access
- 14 October 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Abstract
The TDP-43 proteinopathies, which include amyotrophic lateral sclerosis and frontotemporal dementia, are a devastating group of neurodegenerative disorders that are characterized by the mislocalization and aggregation of TDP-43. Here we demonstrate that RNA-targeting CRISPR effector proteins, a programmable class of gene silencing agents that includes the Cas13 family of enzymes and Cas7–11, can be used to mitigate TDP-43 pathology when programmed to target ataxin-2, a modifier of TDP-43-associated toxicity. In addition to inhibiting the aggregation and transit of TDP-43 to stress granules, we find that the in vivo delivery of an ataxin-2-targeting Cas13 system to a mouse model of TDP-43 proteinopathy improved functional deficits, extended survival, and reduced the severity of neuropathological hallmarks. Further, we benchmark RNA-targeting CRISPR platforms against ataxin-2 and find that high-fidelity forms of Cas13 possess improved transcriptome-wide specificity compared to Cas7–11 and a first-generation effector. Our results demonstrate the potential of CRISPR technology for TDP-43 proteinopathies.Keywords
All Related Versions
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1U01NS122102-01A1, 1R01NS123556-01A1)
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (5R01GM141296)
- Muscular Dystrophy Association (MDA602798)
- Simons Foundation (887187)
- Parkinson’s Disease Foundation (PF-IMP-1950)
- U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (T32EB019944)
- The Judith & Jean Pape Adams Foundation
This publication has 105 references indexed in Scilit:
- Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease modelsNature Genetics, 2012
- TDP-43 aggregation in neurodegeneration: Are stress granules the key?Brain Research, 2012
- TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathiesTrends in Molecular Medicine, 2011
- Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43Nature Neuroscience, 2011
- Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALSNature, 2010
- Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesisActa Neuropathologica, 2010
- Rethinking ALS: The FUS about TDP-43Cell, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicityProceedings of the National Academy of Sciences, 2008